Abbott gains more rights to Sonus agent

Article

Sonus Pharmaceuticals of Bothell, WA, has granted U.S. marketingpartner Abbott Laboratories licensing rights to its EchoGen ultrasoundcontrast agent in all international territories outside Japanand nine other Asia-Pacific countries. In exchange for the

Sonus Pharmaceuticals of Bothell, WA, has granted U.S. marketingpartner Abbott Laboratories licensing rights to its EchoGen ultrasoundcontrast agent in all international territories outside Japanand nine other Asia-Pacific countries. In exchange for the internationalrights, Abbott, of Abbott Park, IL, has agreed to make $34.6 millionin license and milestone payments, some of which will be creditedagainst future royalties.

Sonus and Abbott in May reached a pact covering EchoGen salesin the U.S. (SCAN 5/22/96). With this latest deal, Abbott gainsEchoGen marketing rights to additional territories, includingEurope, the rights to which Sonus regained from French contrastfirm Guerbet earlier this year (SCAN 9/11/96). Daiichi Pharmaceuticalhas marketing rights in Pacific Rim countries.

Sonus has filed a new drug application for EchoGen with theFood and Drug Administration and plans to file for European regulatoryapproval of the product by the end of this year.

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.